Bellco srl Lynda CRRT machine CVVH PEX - PowerPoint PPT Presentation

About This Presentation
Title:

Bellco srl Lynda CRRT machine CVVH PEX

Description:

Title: Presentazione di PowerPoint Author: Bellco Last modified by: Ethar Ismail Created Date: 12/2/2004 4:54:11 PM Document presentation format: On-screen Show (4:3) – PowerPoint PPT presentation

Number of Views:650
Avg rating:3.0/5.0
Slides: 29
Provided by: Bel126
Category:

less

Transcript and Presenter's Notes

Title: Bellco srl Lynda CRRT machine CVVH PEX


1
Bellco srlLynda CRRT machineCVVH PEX
CPFA Presentation
2
Versatile for the physician, functional for the
nurse, effective for the patient. A simple answer
to complex questions from the Abyle line
3
(No Transcript)
4
Therapeutic versatility
  • Wide range of options

Technological innovation, the wide range of
therapies and ease of use are the essential
features of Lynda
5
Therapeutic versatility
  • Wide range of options
  • Continual monitoring of hematocrit and oxygen
    saturation
  • The HCT (with blood volume calculation) and the
    SO2 can directly and continuously be measured
    through a high-precision instrument (closed
    system with cuvette integrated in the arterial
    line).

A sensor measures a physical quantity. An
application interprets the measurement and gives
it a clinical meaning
6
Therapeutic versatility
  • Wide range of options
  • Continual monitoring of hematocrit and
    oxygen saturation
  • Program the infusion system in
  • pre-dilution, post-dilution,
  • or pre-post dilution simultaneously

7
Therapeutic versatility
  • Wide range of options
  • Continual monitoring of hematocrit and oxygen
    saturation
  • Program the infusion system in pre-dilution,
    post-dilution, or pre-post dilution
    simultaneously
  • Filtration fraction control (ff).

8
Therapeutic versatility
  • Wide range of options
  • Continual monitoring of hematocrit and oxygen
    saturation
  • Program the infusion system in pre-dilution,
    post-dilution, or pre-post dilution
    simultaneously
  • Filtration fraction control (ff).
  • History file (over 300 hours capacity).
  • The most important information on the therapies
    performed, the clinical parameter settings, the
    pressure and infused fluid volume graphs

9
Functionality
  •  Automatic priming in all treatment methods.

10
Functionality
  •  Automatic priming in all treatment methods.
  •  On-line guide for the operator to check all the
    sequences instant by instant.

11
Functionality
  •  Automatic priming in all treatment methods.
  •  On-line guide for the operator to check all the
    sequences instant by instant.
  • High-visibility display with user-friendly
    and intuitive touch screen
    interface, which
    allows clear, fast and direct
    dialogue with the
    machine.

12
Functionality
  •  Automatic priming in all treatment methods.
  •  On-line guide for the operator to check all the
    sequences instant by instant.
  • High-visibility display with user-friendly and
    intuitive touch screen interface, which allows
    clear, fast and direct
    dialogue with the machine.
  • Autonomy of 40 litres of controlled exchange
    between two scales, saving
    time and reducing
    the possibility of error

13
Effectiveness
  • Bicompartmental bag

  • The bag is composed of two separate compartments
    one for the bicarbonate buffer (5000 mL) and the
    other for the electrolytes (500 mL). The contents
    are mixed just before use.
  • Two simple operations allow obtaining a solution
    that remains stable up to 24 hours
  • - Breakage of the septum separating the two
    compartments
  • Brief agitation to encourage mixing and obtain a
    homogeneous solution.

14
Effectiveness
  • The disposable Plug Play system,
    comprising preconnected filter/s and
    lines for all the treatment methods, simplifies
    and speeds up the installation operations and
    reduces the possibility of error.

15
SCUF(SLOW CONTINUOUS ULTRAFILTRATION)
Uf
EMOFILTRO
16
CVVH, IHF-HVHF(CONTINUOUS VENO-VENOUS
HEMOFILTRATION, INTERMITTENT HEMO FILTRATION
HIGH VOLUME HEMOFILTRATION, SINGLE NEEDLE
HEMOFILTRATION)
Post diluizione (20100)
Uf
EMOFILTRO
Infusione o anticoagulante
Pre diluizione (080)
17
SN HF(SINGLE NEEDLE HEMOFILTRATION)
Uf
EMOFILTRO
Infusione o anticoagulante
18
PEX (PLASMA EXCHANGE)
Liquido di sostituzione
Post diluizione
Plasma
PLASMAFILTRO
19
CPFA
anticoagulante
20
Effectiveness
  • Disposable Plug Play
  • CPFA a targeted response to sepsis

21
What is Sepsis ?ACCP/SCCM Consensus Definitions
  • Severe Sepsis
  • Sepsis
  • Organ dysfunction
  • Septic shock
  • Sepsis
  • Hypotension despite fluid resuscitation
  • Multiple Organ Dysfunction Syndrome (MODS)
  • Altered organ function in an acutely ill patient
  • Homeostasis cannot be maintained without
    intervention
  • Infection
  • Inflammatory response to microorganisms, or
  • Invasion of normally sterile tissues
  • Systemic Inflammatory Response Syndrome (SIRS)
  • Systemic response to a variety of processes
  • Sepsis
  • Infection plus
  • ?2 SIRS criteria

Bone RC et al. Chest. 19921011644-55.
22
Therapeutic Strategies
Systemic inflammatory response
Multi-organ dysfunction
Infection
Endothelial Dysfunction
Cell activation
Eliminate infection antibiotics
Reduce systemic reaction Steroids Insulin
(glucose control) Xigris
Support organs Ventilation CRRT
IV fluids Vasopressors
23
Coupled Plasma Filtration Adsorption
Plasma
UF out
reinfusion in
24
Therapeutic goal
Separate and retain toxins from a complex
mixture
Time 0
later
toxins
Physiologicalgood molecules
25
Ideal therapy for sepsis
Plasma
bad molecules
good molecules
Dialysate out
Dialysate in
26
What can the CPFA resin adsorb?
  • Macrophage inflammatory protein-a (MIP-a)
  • Macrophage inflammatory protein-b (MIP-b)
  • Tumor necrosis factor-aTNF-a
  • Monocyte chemotactic protein (MCP-1)
  • RANTES
  • Epithelial neutrophil activating peptide 78
    (ENA-78)
  • Angiogenin
  • Interleukin 1b
  • Interleukin 5
  • Interleukin 6
  • Interleukin 7
  • Interleukin 8
  • Interleukin 10(?)
  • Interleukin 12p70
  • Interleukin 16
  • Interleukin 18

27
CPFA used successfully in non-ARF patients
Hemodynamic response to coupled
plasmafiltration-adsorption in human septic shock
Marco Formica, Carlo Olivieri, Sergio Livigni,
Giulio Cesano, Antonella Vallero, Mariella Maio
and Ciro Tetta
Intensive Care Med (2003) 29 703-708
Objective The objective was to examine the
effect of repeated applications of coupled
plasmafiltration-adsorption on the hemodynamic
response in septic shock patients hospitalized in
intensive care units (ICUs).
Conclusion Coupled plasmafiltration-adsorption
was a feasible and safe extracorporeal treatment
and exerted a remarkable improvement in the
hemodynamics, the pulmonary function, and the
outcome in septic shock patients with or without
concomitant ARF.
28
What is not adsorbed to the resin
  • No significant adsorption of
  • Albumin
  • Heparin
  • Citrate
  • Antibodies
  • Ferritin
  • GM-CSF
  • Thyroxine
  • Adiponectin
  • Von Willebrand factor
  • Endotoxin
  • Low Adsorption
  • Insulin (1st hour)
  • VEGF
  • EGF
  • ICAM
  • VCAM
  • MCP
Write a Comment
User Comments (0)
About PowerShow.com